Jerome Galon on the Prognostic Value of Immunoscore

Jerome Galon, PhD, research director at Inserm and head of the Laboratory of Integrative Cancer Immunology, discusses the prognostic value of the Immunoscore®Colon assay and its corresponding validation study, which was presented during the 2016 ASCO Annual Meeting.

Immunoscore® has been a project in development since 2005 to stratify patients into high- and low-risk categories. Results of an international validation study, which tested Immunoscore® in 3855 patients, demonstrated its prognostic value in patients with stage I, II, and III colon cancer.

Highlights of the ASCO presentation entitled “Validation of the Immunoscore® as a prognostic marker in stage I/II/III colon cancer” were that primary endpoint of the study has been reached, with significantly longer time to recurrence for patients classified as Immunoscore-High. Immunoscore® was also able to predict disease-free survival and overall survival among stage I, II, and III patients with colon cancer and importantly, in stage II patients, the Immunoscore® classification identified a subgroup of high-risk patients.